Determinants of cardiac myosin binding protein C in the general population

Description

The webinar will present our article using data from a population-based Norwegian age cohort study of more than 3700 individuals, assessing potential determinants of cardiac myosin binding protein C (cMyC). We identify demographic and clinical determinants of cMyC and investigate the relationship between imaging signs of structural myocardial disease and cMyC in the presumably healthy, general population.

Our work is an early step in utilizing concentrations of this novel cardiac biomarker to identify individuals in the general population who are at increased risk of cardiovascular disease. By participating in the webinar, we hope you will join in considering the implications of our results and evaluate the use of cardiac myosin binding protein C in cardiovascular risk assessment of the general population.

Read the article in Clinical Chemistry.

Target audience

This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), medical technologists, point-of-care coordinators, pathologists, toxicologists, fellows, residents, in-training individuals, and other laboratory professionals overseeing/conducting within this topic.

Learning objectives

At the end of this session, participants will be able to:

• Recognize which demographic and clinical determinants are associated with increased concentrations of cardiac myosin binding protein C in a population-based cohort.
• Identify the relationships between cardiac myosin binding protein C and imaging markers of left ventricular remodeling and myocardial fibrosis in the general population.
• Point out similarities and differences between cardiac myosin binding protein C and cardiac troponins.

Faculty

Moderator

Jason Park, MD, PhD
Editor-in-Chief, Clinical Chemistry
Robin M. Jacoby, Ph.D. Professorship in Biomedical Science
Professor, Pathology and the Eugene McDermott Center for Human Growth and Development
University of Texas Southwestern Medical Center
Dallas, TX

Speaker

Michael Paus, MD
Research Fellow
Akershus University Hospital
Oslo, Norway

Disclosures and Statement of Independence

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.

The following faculty reported financial relationships:

• Michael Paus, MD
  • Honorarium/Expenses: Abbott Diagnostics
• Jason Park, MD, PhD
  • Ownership interest: OncoSeer Dx 

Content Validity

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

Accreditation Statement

This activity is approved for 0.75 ACCENT® continuing education credits. Activity ID #4391. This activity was planned in accordance with ACCENT® Standards and Policies.

Successful Completion Statement

Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].